Detail akcie Xeris Biph Hldg Rg online

Business Summary: Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Xeris Biopharma Holdings Inc revenues increased 44% to $206M. Net loss decreased 79% to $10.5M. Revenues reflect Product revenue -Recorlev segment increase from $36.1M to $93.9M, Product revenue - Gvoke segment increase of 17% to $69.5M. Lower net loss reflects Debt refinancing costs decrease from $2.7M (expense) to $0K, Interest expense decrease of 4% to $21.9M (expense).